Beika Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Beika Zhu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Karl Herrup
Department of Neurobiology, School of Medicine, University of Pittsburgh, Pittsburgh, USA
4 shared publications - Xianhua Piao
Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA
4 shared publications Alicia L. Thurber
Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA
2 shared publicationsAndi Wangzhou
Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, CA USA
2 shared publications- Pei-Yuan Qian
Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou), Guangzhou 511458, China
2 shared publications Tao Li
Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, CA USA
2 shared publications
Latest Publications
- Open Access
Pre-myelinating oligodendrocyte ADGRG1 is required for axon ensheathment and CNS myelin formation
Myelin is essential for axonal health and rapid propagation of action potentials. In the central nervous system (CNS), myelination is initiated with axon ensheathment by pre-myelinating oligodendrocytes (preOLs), followed by iterative membrane wrapping and longitudinal extension along the axon. The molecular mechanisms that govern preOL development remain largely unknown. In this study, we identify the adhesion G protein–coupled receptor ADGRG1 (also called GPR56) as a key, evolutionarily conserved regulator of this process. We show that ADGRG1 is highly expressed in preOLs and that its conditional deletion in mouse preOLs leads to simplified preOL morphology and defective axon ensheathment, resulting in CNS hypomyelination. Live imaging in zebrafish demonstrated conserved function of Adgrg1 in axon ensheathment. Mechanistically, we show that ADGRG1 promotes preOL maturation by RhoA activation. Collectively, these findings reveal an ADGRG1-mediated RhoA signaling pathway that governs axon ensheathment and myelin formation.
Open AccessPre-myelinating oligodendrocyte ADGRG1 is required for axon ensheathment and CNS myelin formation
Myelin is essential for axonal health and rapid propagation of action potentials. In the central nervous system (CNS), myelination is initiated with axon ensheathment by pre-myelinating oligodendrocytes (preOLs), followed by iterative membrane wrapping and longitudinal extension along the axon. The molecular mechanisms that govern preOL development remain largely unknown. In this study, we identify the adhesion G protein–coupled receptor ADGRG1 (also called GPR56) as a key, evolutionarily conserved regulator of this process. We show that ADGRG1 is highly expressed in preOLs and that its conditional deletion in mouse preOLs leads to simplified preOL morphology and defective axon ensheathment, resulting in CNS hypomyelination. Live imaging in zebrafish demonstrated conserved function of Adgrg1 in axon ensheathment. Mechanistically, we show that ADGRG1 promotes preOL maturation by RhoA activation. Collectively, these findings reveal an ADGRG1-mediated RhoA signaling pathway that governs axon ensheathment and myelin formation.
- Open Access
- 24 November 2025
- Published by Elsevier in STAR Protocols
- Vol. 6 (4) , 104219
Protocol for in vitro phagocytosis assay for primary mouse microglia and human embryonic stem cell-derived microglia
- 24 November 2025
- Published by Elsevier in STAR Protocols
- Vol. 6 (4) , 104219
Open AccessProtocol for in vitro phagocytosis assay for primary mouse microglia and human embryonic stem cell-derived microglia
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S1) , e084250
Microglial ADGRG1/GPR56 regulates amyloid clearance in Alzheimer’s disease
Background: Alzheimer’s disease (AD) is a devastating neurodegenerative disease with virtually no therapeutic interventions to reverse its pathology. Emerging studies emphasize the role of glial cells, particularly microglia, in brain homeostasis and AD progression. Notably, the adhesion G protein‐coupled receptor GPR56 (also known as ADGRG1) is one of the critical genes defining yolk sac‐derived microglia. Recent single‐nucleus RNA sequencing (snRNAseq) studies have shown GPR56, as one of the top five genes upregulated in microglia in individuals with early‐stage AD compared to those with no pathology or late‐stage AD. This observation suggests that individuals with upregulated microglial GPR56‐mediated pathways may have survived to an advanced age with mild AD pathology. In the present study, we test the hypothesis that microglial GPR56 is critical in modulating the microglial response in AD.Method: We developed a novel AD mouse model with specific deletion of GPR56 in the microglia of 5xFAD mice (designated AD‐cKO and AD‐Control). Comprehensive analyses, including immunostaining, behavioral tests, and snRNAseq, were employed. The impact of GPR56 on microglial phagocytosis was evaluated using both in vitro and in vivo assays.Result: Absence of microglial GPR56 exacerbated AD pathology, characterized by a compromised microglial response, increased plaque burden, exacerbated neuronal pathology, and cognitive deficits. snRNAseq analysis revealed a downregulation of genes associated with microglial homeostasis, phagocytosis, and lysosomal functions in AD‐cKO mice. Phagocytosis assays showed a significant reduction in phagocytic capability in AD‐cKO microglia. Extending this assay to human iPSC‐derived microglia, we observed a corresponding phenotype in GPR56 KO cells. Pearson correlation coefficient analysis using several published human sequencing databases corroborated our results in mouse models.Conclusion: Our study supports that microglial GPR56 plays an indispensable role in curtailing AD progression, presenting a potential new therapeutic target in combating AD.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S1) , e084250
Open AccessMicroglial ADGRG1/GPR56 regulates amyloid clearance in Alzheimer’s disease
Background: Alzheimer’s disease (AD) is a devastating neurodegenerative disease with virtually no therapeutic interventions to reverse its pathology. Emerging studies emphasize the role of glial cells, particularly microglia, in brain homeostasis and AD progression. Notably, the adhesion G protein‐coupled receptor GPR56 (also known as ADGRG1) is one of the critical genes defining yolk sac‐derived microglia. Recent single‐nucleus RNA sequencing (snRNAseq) studies have shown GPR56, as one of the top five genes upregulated in microglia in individuals with early‐stage AD compared to those with no pathology or late‐stage AD. This observation suggests that individuals with upregulated microglial GPR56‐mediated pathways may have survived to an advanced age with mild AD pathology. In the present study, we test the hypothesis that microglial GPR56 is critical in modulating the microglial response in AD.Method: We developed a novel AD mouse model with specific deletion of GPR56 in the microglia of 5xFAD mice (designated AD‐cKO and AD‐Control). Comprehensive analyses, including immunostaining, behavioral tests, and snRNAseq, were employed. The impact of GPR56 on microglial phagocytosis was evaluated using both in vitro and in vivo assays.Result: Absence of microglial GPR56 exacerbated AD pathology, characterized by a compromised microglial response, increased plaque burden, exacerbated neuronal pathology, and cognitive deficits. snRNAseq analysis revealed a downregulation of genes associated with microglial homeostasis, phagocytosis, and lysosomal functions in AD‐cKO mice. Phagocytosis assays showed a significant reduction in phagocytic capability in AD‐cKO microglia. Extending this assay to human iPSC‐derived microglia, we observed a corresponding phenotype in GPR56 KO cells. Pearson correlation coefficient analysis using several published human sequencing databases corroborated our results in mouse models.Conclusion: Our study supports that microglial GPR56 plays an indispensable role in curtailing AD progression, presenting a potential new therapeutic target in combating AD.
- Open Access
Microglia regulate GABAergic neurogenesis in prenatal human brain through IGF1
GABAergic neurons are an essential cellular component of neural circuits. Their abundance and diversity have enlarged significantly in the human brain, contributing to the expanded cognitive capacity of humans. However, the developmental mechanism of the extended production of GABAergic neurons in the human brain remains elusive. Here, we use single-cell transcriptomics, bioinformatics, and histological analyses to uncover microglial regulation of the sustained proliferation of GABAergic progenitors and neuroblasts in the human medial ganglionic eminence (hMGE). We show that insulin-like growth factor 1 (IGF1) and its receptor IGR1R as the top ligand-receptor pair underlying microglia-progenitor communication in the prenatal human brain. Using our newly developed neuroimmune hMGE organoids, which mimics hMGE cytoarchitecture and developmental trajectory, we demonstrate that microglia-derived IGF1 promotes progenitor proliferation and the production of GABAergic neurons. Conversely, IGF1-neutralizing antibodies and IGF1 knockout human embryonic stem cells (hESC)-induced microglia (iMG) completely abolished iMG-mediated progenitor proliferation. Together, these findings reveal a previously unappreciated role of microglia-derived IGF1 in promoting proliferation of neural progenitors and the development of GABAergic neurons.
Open AccessMicroglia regulate GABAergic neurogenesis in prenatal human brain through IGF1
GABAergic neurons are an essential cellular component of neural circuits. Their abundance and diversity have enlarged significantly in the human brain, contributing to the expanded cognitive capacity of humans. However, the developmental mechanism of the extended production of GABAergic neurons in the human brain remains elusive. Here, we use single-cell transcriptomics, bioinformatics, and histological analyses to uncover microglial regulation of the sustained proliferation of GABAergic progenitors and neuroblasts in the human medial ganglionic eminence (hMGE). We show that insulin-like growth factor 1 (IGF1) and its receptor IGR1R as the top ligand-receptor pair underlying microglia-progenitor communication in the prenatal human brain. Using our newly developed neuroimmune hMGE organoids, which mimics hMGE cytoarchitecture and developmental trajectory, we demonstrate that microglia-derived IGF1 promotes progenitor proliferation and the production of GABAergic neurons. Conversely, IGF1-neutralizing antibodies and IGF1 knockout human embryonic stem cells (hESC)-induced microglia (iMG) completely abolished iMG-mediated progenitor proliferation. Together, these findings reveal a previously unappreciated role of microglia-derived IGF1 in promoting proliferation of neural progenitors and the development of GABAergic neurons.
- Open Access
Myelin pathology in ataxia-telangiectasia is the cell autonomous effect of ATM deficiency in oligodendrocytes
Ataxia-telangiectasia (A-T) is a rare genetic disease caused by mutations in the gene encoding the ATM (ataxia-telangiectasia mutated) protein. Although neuronal degeneration in the cerebellum remains the most prominent sign in A-T pathology, neuroimaging studies reveal myelin abnormalities as early comorbidities. We hypothesize that these myelin defects are the direct consequence of ATM deficiencies in the oligodendrocytes (OL) lineage. We examined samples from ten A-T brains in which the ATM mutations had been mapped by targeted genomic sequencing and from Atm -/- mice. In healthy human cerebellum, we confirmed the presence of ATM in white matter OLs. In A-T, a significant reduction in OL density was found along with a massive astrogliosis. This white matter pathology was recapitulated in Atm -/- mice in an age- and gene dose-dependent fashion. Activated ATM was found expressed both in the nucleus and cytoplasm of OL progenitor cells (OPC) and myelinating mature OL. Its presence in the OL lineage is associated with novel OL-specific functions of the ATM protein affecting all stages of the OL life cycle. Blockage of ATM activity with KU-60019 or inducing DNA damage induced with etoposide altered the cell cycle in self-renewing OPC and triggered ectopic cell cycle re-entry in mature OL in vitro . Further, the differentiation program of OPC is highly sensitive to DNA damage either induced directly or by blocking DNA repair. As much of the impact of ATM deficiency in OL is independent of neuronal loss, our findings have important implications for the complex neurological symptoms of human A-T. HIGHLIGHTS: Oligodendrocytes are highly vulnerable to DNA double strand breaks ATM regulates cell cycle control and differentiation of oligodendrocytes Myelin-pathology in Ataxia Telangiectasia is likely the cell-autonomous consequence of ATM deficiency in oligodendrocytes
Open AccessMyelin pathology in ataxia-telangiectasia is the cell autonomous effect of ATM deficiency in oligodendrocytes
Ataxia-telangiectasia (A-T) is a rare genetic disease caused by mutations in the gene encoding the ATM (ataxia-telangiectasia mutated) protein. Although neuronal degeneration in the cerebellum remains the most prominent sign in A-T pathology, neuroimaging studies reveal myelin abnormalities as early comorbidities. We hypothesize that these myelin defects are the direct consequence of ATM deficiencies in the oligodendrocytes (OL) lineage. We examined samples from ten A-T brains in which the ATM mutations had been mapped by targeted genomic sequencing and from Atm -/- mice. In healthy human cerebellum, we confirmed the presence of ATM in white matter OLs. In A-T, a significant reduction in OL density was found along with a massive astrogliosis. This white matter pathology was recapitulated in Atm -/- mice in an age- and gene dose-dependent fashion. Activated ATM was found expressed both in the nucleus and cytoplasm of OL progenitor cells (OPC) and myelinating mature OL. Its presence in the OL lineage is associated with novel OL-specific functions of the ATM protein affecting all stages of the OL life cycle. Blockage of ATM activity with KU-60019 or inducing DNA damage induced with etoposide altered the cell cycle in self-renewing OPC and triggered ectopic cell cycle re-entry in mature OL in vitro . Further, the differentiation program of OPC is highly sensitive to DNA damage either induced directly or by blocking DNA repair. As much of the impact of ATM deficiency in OL is independent of neuronal loss, our findings have important implications for the complex neurological symptoms of human A-T. HIGHLIGHTS: Oligodendrocytes are highly vulnerable to DNA double strand breaks ATM regulates cell cycle control and differentiation of oligodendrocytes Myelin-pathology in Ataxia Telangiectasia is likely the cell-autonomous consequence of ATM deficiency in oligodendrocytes
- Open Access
- 22 January 2021
- Published by Society for Neuroscience in eneuro
- Vol. 8 (2)
Identifying a Population of Glial Progenitors That Have Been Mistaken for Neurons in Embryonic Mouse Cortical Culture
Experiments in primary culture have helped advance our understanding of the curious phenomenon of cell cycle-related neuronal death. In a differentiated postmitotic cell such as a neuron, aberrant cell cycle reentry is strongly associated with apoptosis. Indeed, in many pathologic conditions, neuronal populations at risk for death are marked by cells engaged in a cell cycle like process. The evidence for this conclusion is typically based on finding MAP2+cells that are also positive for cell cycle-related proteins (e.g., cyclin D) or have incorporated thymidine analogs such as bromodeoxyuridine (BrdU) or 5-ethynyl-2’-deoxyuridine (EdU) into their nuclei. We now report that we and others may have partly been led astray in pursuing this line of work. Morphometric analysis of mouse embryonic cortical cultures reveals that the size of the “cycling” MAP2+cells is significantly smaller than those of normal neurons, and their expression of MAP2 is significantly lower. This led us to ask whether, rather than representing fully developed neurons, they more closely resembled precursor-like cells. In support of this idea, we find that these small MAP2+cells are immunopositive for nestin, a neuronal precursor marker, Olig2, an oligodendrocyte lineage marker, and neural/glial antigen 2 (NG2), an oligodendrocyte precursor marker. Tracking their behavior in culture, we find that they predominantly give rise to GFAP+ astrocytes instead of neurons or oligodendrocytes. These findings argue for a critical reexamination of previous reports of stimuli that lead to neuronal cell cycle-related death in primary cultures.
- 22 January 2021
- Published by Society for Neuroscience in eneuro
- Vol. 8 (2)
Open AccessIdentifying a Population of Glial Progenitors That Have Been Mistaken for Neurons in Embryonic Mouse Cortical Culture
Experiments in primary culture have helped advance our understanding of the curious phenomenon of cell cycle-related neuronal death. In a differentiated postmitotic cell such as a neuron, aberrant cell cycle reentry is strongly associated with apoptosis. Indeed, in many pathologic conditions, neuronal populations at risk for death are marked by cells engaged in a cell cycle like process. The evidence for this conclusion is typically based on finding MAP2+cells that are also positive for cell cycle-related proteins (e.g., cyclin D) or have incorporated thymidine analogs such as bromodeoxyuridine (BrdU) or 5-ethynyl-2’-deoxyuridine (EdU) into their nuclei. We now report that we and others may have partly been led astray in pursuing this line of work. Morphometric analysis of mouse embryonic cortical cultures reveals that the size of the “cycling” MAP2+cells is significantly smaller than those of normal neurons, and their expression of MAP2 is significantly lower. This led us to ask whether, rather than representing fully developed neurons, they more closely resembled precursor-like cells. In support of this idea, we find that these small MAP2+cells are immunopositive for nestin, a neuronal precursor marker, Olig2, an oligodendrocyte lineage marker, and neural/glial antigen 2 (NG2), an oligodendrocyte precursor marker. Tracking their behavior in culture, we find that they predominantly give rise to GFAP+ astrocytes instead of neurons or oligodendrocytes. These findings argue for a critical reexamination of previous reports of stimuli that lead to neuronal cell cycle-related death in primary cultures.
- Open Access
- 1 December 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (50) , 19246-19254
GAIN domain–mediated cleavage is required for activation of G protein–coupled receptor 56 (GPR56) by its natural ligands and a small-molecule agonist
- 1 December 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (50) , 19246-19254
Open AccessGAIN domain–mediated cleavage is required for activation of G protein–coupled receptor 56 (GPR56) by its natural ligands and a small-molecule agonist
- Open Access
- 5 August 2019
- Published by Wiley in Journal of Neurochemistry
- Vol. 152 (4) , 493-508
Marine bacterial extracts as a new rich source of drugs against Alzheimer’s disease
Alzheimer's disease (AD) is a prevalent, progressive and irreversible, neurodegenerative disease with no disease modifying treatment yet available. The projected burden of AD on our healthcare system is immense and thus there is an immediate need for new drugs that prevent or attenuate AD symptoms. While most efforts in the field are directed at treatments that reduce amyloid or tau burden in the brain, we have taken an alternate approach – a model based on reducing AD‐associated neuronal cell cycle events. Using this model, we have screened a largely unexplored source of compounds with therapeutic potential – the natural products created by diverse strains of marine bacteria. Two hundred and twenty‐five bacterial extracts from different strains were tested for both toxicity and neuroprotective properties by crystal violet and In‐cell Western – first in HT22 cells and then in mouse primary neuronal cultures. Based on these screens, we have identified several promising leads, and here we focus on the most promising of these. We found that we could directly assay even a crude bacterial extract in our E16 mouse cortical neuronal cultures and screen for activities that prevent cell cycle reentry and preserve synaptic structure. Preliminary tests in 1‐month‐old animals from a mouse model of Ataxia telangiectasia, showed that blockage of cell cycle‐related neuronal death could also be successful in vivo. This adds an important extension to our in vitro studies. These findings showcase a new effective and efficient assay system and validate the use of marine natural compounds as a novel source for new drugs to fight Alzheimer’s disease. image Cover Image for this issue: doi: 10.1111/jnc.14733.
- 5 August 2019
- Published by Wiley in Journal of Neurochemistry
- Vol. 152 (4) , 493-508
Open AccessMarine bacterial extracts as a new rich source of drugs against Alzheimer’s disease
Alzheimer's disease (AD) is a prevalent, progressive and irreversible, neurodegenerative disease with no disease modifying treatment yet available. The projected burden of AD on our healthcare system is immense and thus there is an immediate need for new drugs that prevent or attenuate AD symptoms. While most efforts in the field are directed at treatments that reduce amyloid or tau burden in the brain, we have taken an alternate approach – a model based on reducing AD‐associated neuronal cell cycle events. Using this model, we have screened a largely unexplored source of compounds with therapeutic potential – the natural products created by diverse strains of marine bacteria. Two hundred and twenty‐five bacterial extracts from different strains were tested for both toxicity and neuroprotective properties by crystal violet and In‐cell Western – first in HT22 cells and then in mouse primary neuronal cultures. Based on these screens, we have identified several promising leads, and here we focus on the most promising of these. We found that we could directly assay even a crude bacterial extract in our E16 mouse cortical neuronal cultures and screen for activities that prevent cell cycle reentry and preserve synaptic structure. Preliminary tests in 1‐month‐old animals from a mouse model of Ataxia telangiectasia, showed that blockage of cell cycle‐related neuronal death could also be successful in vivo. This adds an important extension to our in vitro studies. These findings showcase a new effective and efficient assay system and validate the use of marine natural compounds as a novel source for new drugs to fight Alzheimer’s disease. image Cover Image for this issue: doi: 10.1111/jnc.14733.
- Open Access
- 24 January 2019
- Published by MDPI AG in Marine Drugs
- Vol. 17 (2) , 79
Testing the Neuroprotective Properties of PCSO-524® Using a Neuronal Cell Cycle Suppression Assay
Cell cycle reentry is a unified mechanism shared by several neurodegenerative diseases, including Alzheimer’s disease (AD) and Ataxia Telangiectasia (A-T). This phenotype is often related to neuroinflammation in the central nervous system. To mimic brain inflammation in vitro, we adopted the previously established method of using conditioned medium collected from activated THP-1 cells and applied it to both differentiated HT22 cells and primary neurons. Unscheduled cell cycle events were observed in both systems, indicating the potential of this approach as an in vitro model of neurodegenerative disease. We used this assay to measure the neuroprotective effects of New Zealand green-lipped mussel extract, PCSO-524®, to protect post-mitotic cells from cell cycle reentry. We found that, both in vitro and in an animal model, PCSO-524® displayed promising neuroprotective effects, and thus has potential to postpone or prevent the onset of neurodegenerative disease.
- 24 January 2019
- Published by MDPI AG in Marine Drugs
- Vol. 17 (2) , 79
Open AccessTesting the Neuroprotective Properties of PCSO-524® Using a Neuronal Cell Cycle Suppression Assay
Cell cycle reentry is a unified mechanism shared by several neurodegenerative diseases, including Alzheimer’s disease (AD) and Ataxia Telangiectasia (A-T). This phenotype is often related to neuroinflammation in the central nervous system. To mimic brain inflammation in vitro, we adopted the previously established method of using conditioned medium collected from activated THP-1 cells and applied it to both differentiated HT22 cells and primary neurons. Unscheduled cell cycle events were observed in both systems, indicating the potential of this approach as an in vitro model of neurodegenerative disease. We used this assay to measure the neuroprotective effects of New Zealand green-lipped mussel extract, PCSO-524®, to protect post-mitotic cells from cell cycle reentry. We found that, both in vitro and in an animal model, PCSO-524® displayed promising neuroprotective effects, and thus has potential to postpone or prevent the onset of neurodegenerative disease.
- Open Access
- 1 December 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (53) , 27228-27238
Family-wide Structural Characterization and Genomic Comparisons Decode the Diversity-oriented Biosynthesis of Thalassospiramides by Marine Proteobacteria
- 1 December 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (53) , 27228-27238
Open AccessFamily-wide Structural Characterization and Genomic Comparisons Decode the Diversity-oriented Biosynthesis of Thalassospiramides by Marine Proteobacteria